Immunome, Inc. (IMNM)
NASDAQ: IMNM · Real-Time Price · USD
18.95
+0.19 (1.01%)
Oct 29, 2026, 10:30 AM EDT - Market open
Immunome Employees
Immunome had 247 employees as of June 30, 2026. The number of employees increased by 92 or 59.35% compared to the same quarter last year. That makes Immunome the 25,282nd largest employer in the world and 3,235th in the United States.
Employees
247
Change (1Y)
92
Growth (1Y)
59.35%
Revenue / Employee
n/a
Profits / Employee
-$1,029,648
Market Cap
2.15B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 247 | 92 | 59.35% |
| Mar 31, 2026 | 206 | 75 | 57.25% |
| Dec 31, 2025 | 177 | 59 | 50.00% |
| Sep 30, 2025 | 168 | 63 | 60.00% |
| Jun 30, 2025 | 155 | 77 | 98.72% |
| Mar 31, 2025 | 131 | 69 | 111.29% |
| Dec 31, 2024 | 118 | 63 | 114.55% |
| Sep 30, 2024 | 105 | 50 | 90.91% |
| Jun 30, 2024 | 78 | - | - |
| Mar 31, 2024 | 62 | 25 | 67.57% |
| Dec 31, 2023 | 55 | 18 | 48.65% |
| Dec 31, 2022 | 37 | -2 | -5.13% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Maravai LifeSciences Holdings | 415 |
| Vericel | 398 |
| Vera Therapeutics | 361 |
| Harmony Biosciences Holdings | 293 |
| Xencor | 260 |
| Zymeworks | 231 |
| Lakefront Biotherapeutics NV | 196 |
| Precigen | 160 |
IMNM News
- 3 days ago - Immunome presents additional clinical data for varegacestat at ESMO 2026 - TheFly
- 3 days ago - Immunome Presents Additional Clinical Data for Varegacestat in Desmoid Tumors at ESMO 2026 - Business Wire
- 13 days ago - Immunome initiated with an Outperform at William Blair - TheFly
- 22 days ago - Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 4 weeks ago - Immunome initiated with a Hold at Stifel - TheFly
- 4 weeks ago - Immunome announces IND clearance for IM-1340 in solid tumors - TheFly
- 4 weeks ago - Immunome Announces IND Clearance for IM-1340, a Potential First-in-Class Antibody-Drug Conjugate for the Treatment of Solid Tumors - Business Wire
- 5 weeks ago - Immunome initiated with a Buy at Alliance Global - TheFly